MX389834B - Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer. - Google Patents

Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.

Info

Publication number
MX389834B
MX389834B MX2017016931A MX2017016931A MX389834B MX 389834 B MX389834 B MX 389834B MX 2017016931 A MX2017016931 A MX 2017016931A MX 2017016931 A MX2017016931 A MX 2017016931A MX 389834 B MX389834 B MX 389834B
Authority
MX
Mexico
Prior art keywords
whole cell
mycobaterium
cancer therapy
checkpoint inhibitor
immunomodulator
Prior art date
Application number
MX2017016931A
Other languages
English (en)
Other versions
MX2017016931A (es
Inventor
Charles Akle
Laura Rosa Brunet
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511121.4A external-priority patent/GB201511121D0/en
Priority claimed from GBGB1511120.6A external-priority patent/GB201511120D0/en
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Publication of MX2017016931A publication Critical patent/MX2017016931A/es
Publication of MX389834B publication Critical patent/MX389834B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe un inmunomodulador para uso en el tratamiento, reducción, inhibición o control de una enfermedad neoplásica en un paciente que pretende experimentar terapia de inhibición del punto de regulación, seleccionado de una célula, proteína, péptido, anticuerpo o fragmento de enlace al antígeno del mismo, dirigido contra CTLA-4, PD-1, PD-L1 y combinaciones de los mismos, simultáneamente, separadamente o secuencialmente con administración del inmunomodulador. El inmunomodulador comprende un Mycobacteriurn de célula entera, por ejemplo, M. vaccae o M. obuense.
MX2017016931A 2015-06-24 2016-06-24 Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer. MX389834B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1511121.4A GB201511121D0 (en) 2015-06-24 2015-06-24 Cancer therapy
GBGB1511120.6A GB201511120D0 (en) 2015-06-24 2015-06-24 Cancer therapy
PCT/GB2016/051893 WO2016207646A1 (en) 2015-06-24 2016-06-24 A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy

Publications (2)

Publication Number Publication Date
MX2017016931A MX2017016931A (es) 2018-09-26
MX389834B true MX389834B (es) 2025-03-20

Family

ID=56296853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016931A MX389834B (es) 2015-06-24 2016-06-24 Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.

Country Status (13)

Country Link
US (2) US11207405B2 (es)
EP (2) EP3868406A1 (es)
JP (3) JP6892443B2 (es)
KR (1) KR20180015269A (es)
CN (2) CN114344462B (es)
AU (1) AU2016281765B2 (es)
ES (1) ES2879248T3 (es)
IL (1) IL256467B (es)
MX (1) MX389834B (es)
PL (1) PL3319635T3 (es)
PT (1) PT3319635T (es)
RU (1) RU2733033C2 (es)
WO (1) WO2016207646A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
JP6430683B2 (ja) * 2016-12-19 2018-11-28 昭和電工株式会社 レドックスフロー電池の運転方法
KR102713203B1 (ko) * 2017-05-30 2024-10-10 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
EP3421607A1 (en) * 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
US20210239955A1 (en) * 2018-06-08 2021-08-05 The Board Of Trustees Of The Leland Stanford Junior University Near infra-red light sheet microscopy through scattering tissues
GB201810058D0 (en) * 2018-06-19 2018-08-08 Cytovation As Combination therapy using a peptide
US20210299187A1 (en) * 2018-06-25 2021-09-30 Immodulon Therapeutics Limited Cancer therapy
GB201919428D0 (en) * 2019-12-30 2020-02-12 Immodulon Therapeutics Ltd Immunotherapeutic treatment of cancer
EP4240383A1 (en) * 2020-11-06 2023-09-13 Immodulon Therapeutics Limited Mycobacterial immunotherapy for treating cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
AU660430B2 (en) 1990-11-08 1995-06-29 Stanford Rook Limited Mycobacterium as adjuvant for antigens
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
KR100533818B1 (ko) * 1996-12-18 2005-12-07 스탠포드 룩 리미티드 면역계의 ｔｈ2 활성의 하향 조절을 위한 마이코박테리움 박케
EP1173203A2 (en) 1999-04-23 2002-01-23 QLT Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
AU2002353366A1 (en) 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
EP2206517B1 (en) * 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
EP2130826A1 (en) 2004-07-13 2009-12-09 The University of British Columbia Annulins A, B, C or analogs as indoleamine 2,3-dioxygenase (IDO) inhibitors for treatment of cancer
EP1863532A1 (en) 2005-03-23 2007-12-12 Pfizer Products Incorporated Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
CA2626547A1 (en) * 2005-10-21 2007-05-03 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
WO2007112316A2 (en) 2006-03-24 2007-10-04 Morton Donald L Mycobacterial immunotherapy for cancer treatment
US8109993B2 (en) 2006-05-25 2012-02-07 Deep Vein Medical, Inc. Device for regulating blood flow
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
JP5310222B2 (ja) 2009-04-20 2013-10-09 富士通株式会社 電荷分配型デジタル・アナログ変換器及びそれを有する逐次比較型アナログ・デジタル変換器
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
AU2012225298B2 (en) 2011-03-09 2017-05-11 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
CA2830806C (en) 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
AU2012273182A1 (en) 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
US9617336B2 (en) 2012-02-01 2017-04-11 Compugen Ltd C10RF32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) * 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US9212224B2 (en) * 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
SI3508502T1 (sl) 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
WO2015061752A1 (en) * 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
KR20220062143A (ko) * 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
BR112017000497B1 (pt) * 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
KR101724963B1 (ko) 2015-12-09 2017-04-10 현대자동차주식회사 전자식 다기능 스위치의 턴신호 제어장치 및 그 제어방법
US20210299187A1 (en) 2018-06-25 2021-09-30 Immodulon Therapeutics Limited Cancer therapy

Also Published As

Publication number Publication date
EP3319635B1 (en) 2021-04-21
US11207405B2 (en) 2021-12-28
CN114344462A (zh) 2022-04-15
CN107847598A (zh) 2018-03-27
EP3868406A1 (en) 2021-08-25
JP6892443B2 (ja) 2021-06-23
RU2018102547A (ru) 2019-07-24
CN114344462B (zh) 2024-08-13
CA2990107A1 (en) 2016-12-29
AU2016281765A1 (en) 2018-01-18
IL256467B (en) 2021-12-01
PT3319635T (pt) 2021-07-07
MX2017016931A (es) 2018-09-26
JP2021120418A (ja) 2021-08-19
JP7393384B2 (ja) 2023-12-06
AU2016281765B2 (en) 2022-06-16
JP2018518539A (ja) 2018-07-12
RU2733033C2 (ru) 2020-09-28
ES2879248T3 (es) 2021-11-22
KR20180015269A (ko) 2018-02-12
JP2023118968A (ja) 2023-08-25
US20180185479A1 (en) 2018-07-05
IL256467A (en) 2018-02-28
EP3319635A1 (en) 2018-05-16
PL3319635T3 (pl) 2021-10-25
WO2016207646A1 (en) 2016-12-29
RU2018102547A3 (es) 2019-12-24
BR112017028163A2 (pt) 2018-08-28
CN107847598B (zh) 2022-01-25
US20220111046A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX389834B (es) Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
MX2016007709A (es) Un inhibidor de punto de control y una celula de mycobacterium para su utilizacion en el tratamiento contra cancer.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2017000554A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
MX2018008514A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
MX2019003780A (es) Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres.
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MX2022008868A (es) Tratamiento del cancer con tg02.
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2017012113A (es) Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
MX2022007962A (es) Anticuerpo anti-lilrb1 y usos del mismo.